In truth, the Viatris class action lawsuit alleges, Viatris' efforts to downplay the ramifications of the failed U.S. Food and Drug Administration ("FDA") inspection fell short of reality, the impact to Viatris' projected fiscal year 2025 finances from the combination of the ongoing remediation efforts at the facility, the inability for the facility to manufacture and ship key products for Viatris, particularly Lenalidomide, the inability for Viatris to convince the FDA to expand the exempt list to include such drugs, and an associated impact on shipments to other regions from the Indore facility was significant and resulted in much more than"a little bit" of a headwind.